☰

Beatrice D. Darimont - Publications

Affiliations: 
University of Oregon, Eugene, OR, United States 
Area:
Molecular Biology, Pharmacology, Biochemistry
Tree Info Similar researchers PubMed Report error

27 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Kahraman M, Govek SP, Nagasawa JY, Lai A, Bonnefous C, Douglas K, Sensintaffar J, Liu N, Lee K, Aparicio A, Kaufman J, Qian J, Shao G, Prudente R, Joseph JD, ... Darimont B, et al. Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927. Acs Medicinal Chemistry Letters. 10: 50-55. PMID 30655946 DOI: 10.1021/Acsmedchemlett.8B00414  0.358
2019 Joseph JD, Darimont B, Zhou W, Arrazate A, Young A, Ingalla E, Walter K, Blake RA, Nonomiya J, Guan Z, Kategaya L, Govek SP, Lai AG, Kahraman M, Brigham D, et al. Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. Elife. 8. PMID 30614786 DOI: 10.7554/Elife.44851  0.377
2018 Govek SP, Bonnefous C, Julien JD, Nagasawa JY, Kahraman M, Lai AG, Douglas KL, Aparicio AM, Darimont BD, Grillot KL, Joseph JD, Kaufman JA, Lee KJ, Lu N, Moon MJ, et al. Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft. Bioorganic & Medicinal Chemistry Letters. PMID 30587451 DOI: 10.1016/J.Bmcl.2018.12.042  0.386
2018 Kahraman M, Govek SP, Nagasawa JY, Lai A, Bonnefous C, Douglas K, Sensintaffar J, Lu N, Lee K, Aparicio A, Kaufman J, Qian J, Shao G, Prudente R, Joseph JD, ... Darimont B, et al. Abstract 1648: Discovery and evolution of orally bioavailable selective estrogen receptor degraders for ER+ breast cancer: From GDC-0810 to GDC-0927 Cancer Research. 78: 1648-1648. DOI: 10.1158/1538-7445.Am2018-1648  0.426
2016 Joseph JD, Darimont B, Zhou W, Arrazate A, Young A, Ingalla E, Walter K, Blake RA, Nonomiya J, Guan Z, Kategaya L, Govek SP, Lai AG, Kahraman M, Brigham D, et al. The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. Elife. 5. PMID 27410477 DOI: 10.7554/Elife.15828  0.405
2015 Govek SP, Nagasawa JY, Douglas KL, Lai AG, Kahraman M, Bonnefous C, Aparicio AM, Darimont BD, Grillot KL, Joseph JD, Kaufman JA, Lee KJ, Lu N, Moon MJ, Prudente RY, et al. Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft. Bioorganic & Medicinal Chemistry Letters. PMID 26463130 DOI: 10.1016/J.Bmcl.2015.09.074  0.384
2015 Lai A, Kahraman M, Govek S, Nagasawa J, Bonnefous C, Julien J, Douglas K, Sensintaffar J, Lu N, Lee KJ, Aparicio A, Kaufman J, Qian J, Shao G, Prudente R, ... ... Darimont B, et al. Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts. Journal of Medicinal Chemistry. 58: 4888-904. PMID 25879485 DOI: 10.1021/Acs.Jmedchem.5B00054  0.416
2015 Joseph J, Govek S, Darimont B, Brigham D, Aparicio A, Bischoff E, Kahraman M, Nannini M, Kaufman J, Lai A, Lee K, Oeh J, Lu N, Zhou W, Moon M, et al. Abstract 5053: Discovery of GDC-0810 a novel, non-steroidal selective estrogen receptor degrader with robust activity in pre-clinical models of endocrine-resistant breast cancer Cancer Research. 75: 5053-5053. DOI: 10.1158/1538-7445.Am2015-5053  0.457
2014 Joseph JD, Darimont B, Govek S, Brigham D, Qian J, Sensintaffar J, Shao G, Aparicio A, Kahraman M, Lai A, Lee K, Lu N, Nagasawa J, Moon M, Rix P, et al. Abstract 4757: A novel class of selective estrogen receptors degraders regresses tumors in pre-clinical models of endocrine-resistant breast cancer Cancer Research. 74: 4757-4757. DOI: 10.1158/1538-7445.Am2014-4757  0.452
2013 Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, Moon M, Maneval EC, Chen I, Darimont B, Hager JH. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discovery. 3: 1020-9. PMID 23779130 DOI: 10.1158/2159-8290.Cd-13-0226  0.343
2013 Joseph JD, Darimont B, Govek S, Brigham D, Aparicio A, Kahraman M, Lai A, Lee K, Lu N, Nagasawa J, Kaufman J, Moon M, Prudente R, Qian J, Sensintaffar J, et al. Abstract A37: A novel class of selective estrogen receptor degraders display activity in pre-clinical models of ERα+ ovarian cancer Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-A37  0.467
2012 Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, ... ... Darimont B, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Research. 72: 1494-503. PMID 22266222 DOI: 10.1158/0008-5472.Can-11-3948  0.36
2012 Darimont B, Lu N, Sensintaffar J, Lee K, Aparicio A, Kaufman J, Bischoff E, Rix P, Heyman R, Smith N, Hager J, Joseph J, Grillot K, Qian J, Gang S, et al. Abstract A4: A novel class of selective ERα degraders acts as full antagonists/ inverse agonists and displays efficacy in pre-clinical models of endocrine-resistant breast cancer and endometrial cancer Clinical Cancer Research. 18. DOI: 10.1158/1078-0432.Mechres-A4  0.436
2012 Hager J, Darimont B, Joseph J, Govek S, Grillot K, Aparicio A, Bischoff E, Kahraman M, Kaufman J, Lai A, Lee K, Lu N, Nagasawa J, Prudente R, Qian J, et al. Abstract P6-04-12: Novel selective estrogen receptors degraders regress tumors in pre-clinical models of endocrine-resistant breast cancer Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P6-04-12  0.449
2011 Darimont B, Govek S, Joseph J, Grillot K, Bischoff E, Aparicio A, Bonnefous C, Douglas K, Julien J, Kahraman M, Kaufman J, Lai A, Lee K, Lu N, Nagasawa J, et al. Abstract A133: A novel class of selective estrogen receptor degraders regresses tumors in preclinical models of endocrine-resistant breast cancer. Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-11-A133  0.459
2008 Takayama S, Hostick U, Haendel M, Eisen J, Darimont B. An F-domain introduced by alternative splicing regulates activity of the zebrafish thyroid hormone receptor alpha. General and Comparative Endocrinology. 155: 176-89. PMID 17583703 DOI: 10.1016/J.Ygcen.2007.04.012  0.549
2007 Ricketson D, Hostick U, Fang L, Yamamoto KR, Darimont BD. A conformational switch in the ligand-binding domain regulates the dependence of the glucocorticoid receptor on Hsp90. Journal of Molecular Biology. 368: 729-41. PMID 17367809 DOI: 10.1016/J.Jmb.2007.02.057  0.361
2006 Fang L, Ricketson D, Getubig L, Darimont B. Unliganded and hormone-bound glucocorticoid receptors interact with distinct hydrophobic sites in the Hsp90 C-terminal domain. Proceedings of the National Academy of Sciences of the United States of America. 103: 18487-92. PMID 17130446 DOI: 10.1073/Pnas.0609163103  0.365
2006 Takayama S, Rogatsky I, Schwarcz LE, Darimont BD. The glucocorticoid receptor represses cyclin D1 by targeting the Tcf-beta-catenin complex. The Journal of Biological Chemistry. 281: 17856-63. PMID 16644723 DOI: 10.1074/Jbc.M602290200  0.457
2003 Rogatsky I, Wang JC, Derynck MK, Nonaka DF, Khodabakhsh DB, Haqq CM, Darimont BD, Garabedian MJ, Yamamoto KR. Target-specific utilization of transcriptional regulatory surfaces by the glucocorticoid receptor. Proceedings of the National Academy of Sciences of the United States of America. 100: 13845-50. PMID 14617768 DOI: 10.1073/Pnas.2336092100  0.415
2003 Darimont BD. Finding specificity within a conserved interaction site. Chemistry & Biology. 10: 675-6. PMID 12954326 DOI: 10.1016/S1074-5521(03)00177-7  0.364
2002 Serber Z, Lai HC, Yang A, Ou HD, Sigal MS, Kelly AE, Darimont BD, Duijf PH, Van Bokhoven H, McKeon F, Dötsch V. A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism. Molecular and Cellular Biology. 22: 8601-11. PMID 12446779 DOI: 10.1128/Mcb.22.24.8601-8611.2002  0.316
2001 Jenkins BD, Pullen CB, Darimont BD. Novel glucocorticoid receptor coactivator effector mechanisms Trends in Endocrinology and Metabolism. 12: 122-126. PMID 11306337 DOI: 10.1016/S1043-2760(00)00357-X  0.464
1999 Hammer GD, Krylova I, Zhang Y, Darimont BD, Simpson K, Weigel NL, Ingraham HA. Phosphorylation of the nuclear receptor SF-1 modulates cofactor recruitment: integration of hormone signaling in reproduction and stress. Molecular Cell. 3: 521-6. PMID 10230405 DOI: 10.1016/S1097-2765(00)80480-3  0.429
1999 Hong H, Darimont BD, Ma H, Yang L, Yamamoto KR, Stallcup MR. An additional region of coactivator GRIP1 required for interaction with the hormone-binding domains of a subset of nuclear receptors. The Journal of Biological Chemistry. 274: 3496-502. PMID 9920895 DOI: 10.1074/Jbc.274.6.3496  0.302
1998 Darimont BD, Wagner RL, Apriletti JW, Stallcup MR, Kushner PJ, Baxter JD, Fletterick RJ, Yamamoto KR. Structure and specificity of nuclear receptor-coactivator interactions. Genes & Development. 12: 3343-56. PMID 9808622 DOI: 10.1101/Gad.12.21.3343  0.384
1995 Sterner R, Dahm A, Darimont B, Ivens A, Liebl W, Kirschner K. (Beta alpha)8-barrel proteins of tryptophan biosynthesis in the hyperthermophile Thermotoga maritima. The Embo Journal. 14: 4395-4402. DOI: 10.1002/J.1460-2075.1995.Tb00118.X  0.337
Show low-probability matches.